Literature DB >> 27997752

Review of the NICE guidelines for multiple myeloma.

G Pratt1, T C Morris2.   

Abstract

In February 2016, the National Institute for Health and Care Excellence (NICE) published guidelines on multiple myeloma. NICE have published numerous guidelines relating to haematology, but this was the first guideline focusing on a single haematological malignancy. The purpose of this review was to highlight the recommendations made in the guideline and the implications for the management of patients in the UK and also internationally. In addition, we review the NICE process and highlight issues around current guideline development.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  Myeloma

Mesh:

Year:  2016        PMID: 27997752     DOI: 10.1111/ijlh.12581

Source DB:  PubMed          Journal:  Int J Lab Hematol        ISSN: 1751-5521            Impact factor:   2.877


  3 in total

1.  A prospective study comparing whole-body skeletal X-ray survey with 18F-FDG-PET/CT, 18F-NaF-PET/CT and whole-body MRI in the detection of bone lesions in multiple myeloma patients.

Authors:  Eva Dyrberg; Helle W Hendel; Gina Al-Farra; Lone Balding; Vibeke B Løgager; Claus Madsen; Henrik S Thomsen
Journal:  Acta Radiol Open       Date:  2017-10-27

2.  Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor.

Authors:  Curly Morris; Christian Chabannon; Tamas Masszi; Nigel Russell; Hareth Nahi; Guido Kobbe; Marta Krejci; Holger W Auner; David Pohlreich; Patrick Hayden; Grzegorz W Basak; Stig Lenhoff; Nicolaas Schaap; Anja van Biezen; Cora Knol; Simona Iacobelli; Qianying Liu; Marina Celanovic; Laurent Garderet; Nicolaus Kröger
Journal:  Bone Marrow Transplant       Date:  2019-09-18       Impact factor: 5.483

3.  Huanglian Jiedu Decoction for treatment of multiple myeloma: A protocol for a systematic review and meta-analysis.

Authors:  Na An; Yiwei Li; Xilian Huang; Can Chen; Yaping Xie
Journal:  Medicine (Baltimore)       Date:  2020-12-18       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.